BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss

Reuters03-04

** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86

** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago

** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago

** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer

** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025

** SNDX's shares have fallen 35% in the last 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2516656665?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 01:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516656665","market":"us","top_or_hot":-1,"title":"BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss</title></head><body><p>** Shares of drug developer Syndax Pharmaceuticals <span>SNDX.O</span> fall 5% to $14.86</p><p>** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago </p><p>** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago </p><p>** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer</p><p>** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025</p><p>** SNDX's shares have fallen 35% in the last 12 months</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Syndax Pharmaceuticals drops on wider quarterly loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-04 01:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss</title></head><body><p>** Shares of drug developer Syndax Pharmaceuticals <span>SNDX.O</span> fall 5% to $14.86</p><p>** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago </p><p>** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago </p><p>** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer</p><p>** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025</p><p>** SNDX's shares have fallen 35% in the last 12 months</p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM16Q:1","article_id":"2516656665","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516656665","pubTimestamp":1741021708,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago ** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago ** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025** SNDX's shares have fallen 35% in the last 12 months  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"BUZZ-Syndax Pharmaceuticals因季度亏损扩大而股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":0.9},"content_text":"BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago ** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago ** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025** SNDX's shares have fallen 35% in the last 12 months (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516656665","isCrawlerRequest":true}